Skip to main content

Table 1 Descriptive analysis of variables according to the three levels

From: Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer

 

Mean (SD) or n (%)

Endocrine therapy adherence (MMAS)

Mean (SD)

r

t or F

p

Total MMAS score

 

6.36 (1.65)

   

Demographic/medical

 Age

50.31 (9.03)

 

.136

 

.050

 Education level

College above

84 (40.8)

6.12 (1.64)

 

1.64

.197

High

90 (43.7)

6.50 (1.56)

Below high

32 (15.5)

6.63 (1.89)

 Marital status

No

20 (9.6)

6.20 (1.35)

 

−.473

.637

Yes

189 (90.4)

6.38 (1.68)

 Employment status

No

117 (56.5)

6.48 (1.57)

 

1.103

.271

Yes

90 (43.5)

6.23 (1.75)

 FAM HX of breast cancer

No

191 (91.0)

6.36 (1.69)

 

−.028

.975

Yes

19 (9.0)

6.37 (1.16)

 

 FAM HX of other cancer

No

127 (60.5)

6.44 (1.64)

 

.856

.393

Yes

83 (39.5)

6.24 (1.66)

 

 Cancer stage

Stage 1–3

184 (87.6)

6.47 (1.59)

 

2.554

.011

Stage 0

26 (12.4)

5.60 (1.89)

 

 Node meta

Negative

145 (69.0)

6.27 (1.68)

 

−1.221

.223

Positive

65 (31.0)

6.57 (1.57)

 

 Type of surgery

Mastectomy

27 (12.9)

6.71 (1.37)

 

1.200

.232

Conservation

183 (87.1)

6.31 (1.68)

 RT

No

33 (15.7)

6.39 (1.60)

 

−.135

.893

Yes

177 (84.3)

6.35 (1.66)

 CT

No

110 (52.4)

6.28 (1.68)

 

.705

.481

Yes

100 (47.6)

6.44 (1.61)

 AET regimen

AI

47 (22.4)

6.79 (1.54)

 

2.068

.040

SERM

163 (77.6)

6.23 (1.66)

 

 Months on ET

 

26.75 (19.79)

 

−.012

 

.858

 FSH level

 

21.83 (24.31)

 

.160

 

.100

General psychological

 Menopause-related symptom (0–44)

13.32 (7.71)

 

−.087

 

.214

 Depression (0–60)

15.56 (9.83)

 

−.204

 

.004

 Fear of progression (12–60)

31.60 (10.79)

 

−.053

 

.458

Endocrine therapy-specific

 Beliefs about AET (10–50)

24.50 (6.47)

 

−.005

 

.945

 Necessity beliefs (5–25)

13.83 (4.17)

 

.235

 

.001

 Concern beliefs (5–25)

10.68 (4.10)

 

−.247

 

.000

 Self-efficacy (0–40)

28.99 (4.41)

 

.187

 

.007

  1. MMAS Morisky Medication Adherence Scale, FAM HX family history, RT radiotherapy, CT chemotherapy, AI aromatase inhibitor, SERM selective estrogen receptor modulator, ET endocrine therapy, FSH follicle-stimulating hormone. Permission for MMAS-8 was obtained from Dr. Morisky and MMAS Research. The Morisky Widget, MMAS-8 and MMAS-4, are protected by US and International Trademark and Copyright laws. Permission for use is required. A license agreement is available from: MMAS Research LLC 14725 NE 20th St. Bellevue WA 98007
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us